Skip to Main Content

Paper Details

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Nat Commun
161
2017
BRCA2, BRCA2 mutations, BRCA2 tumour suppressor, BRCA2-mutant PCa, IDC, MED12, MED12L, PCa, castration, castration-sensitive BRCA2-mutant tumours, genomes, intraductal carcinoma, invasive carcinoma, mCRPC, metastatic castration-resistant prostate cancer, non-, patients, prostate cancer, prostate cancers
Aged, BRCA2 Protein, Carcinoma, Ductal, DNA Mutational Analysis, Epigenesis, Genetic, Evolution, Molecular, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Genomic Instability, Germ-Line Mutation, Heterozygote, Humans, Male, Mediator Complex, Middle Aged, Neoplasm Invasiveness, Prostate, Prostatectomy, Prostatic Neoplasms, Protein Isoforms, Retrospective Studies, Whole Genome Sequencing
Author NameAffiliation
Renea A TaylorBiomedicine Discovery Institute, Monash University
Michael FraserPrincess Margaret Cancer Centre, University Health Network
Julie LivingstoneOntario Institute for Cancer Research
Shadrielle Melijah G EspirituOntario Institute for Cancer Research
Heather ThornePeter MacCallum Cancer Centre
Heather ThorneThe Sir Peter MacCallum Department of Oncology University of Melbourne
Vincent HuangOntario Institute for Cancer Research
Winnie LoPrincess Margaret Cancer Centre, University Health Network
Yu-Jia ShiahOntario Institute for Cancer Research
Takafumi N YamaguchiOntario Institute for Cancer Research
Ania SliwinskiThe Sir Peter MacCallum Department of Oncology University of Melbourne
Ania SliwinskiUniversity of Melbourne, Austin Hospital
Sheri HorsburghPrincess Margaret Cancer Centre, University Health Network
Alice MengPrincess Margaret Cancer Centre, University Health Network
Lawrence E HeislerOntario Institute for Cancer Research
Nancy YuOntario Institute for Cancer Research
Fouad YousifOntario Institute for Cancer Research
Melissa PapargirisMonash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
Mitchell G LawrenceMonash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
Lee TimmsOntario Institute for Cancer Research
Declan G MurphyPeter MacCallum Cancer Centre
Mark FrydenbergMonash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
Julia F HopkinsOntario Institute for Cancer Research
Damien BoltonMonash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
David Clouston
John D McPhersonOntario Institute for Cancer Research
Theodorus H van der KwastPrincess Margaret Cancer Centre, University Health Network
Paul C BoutrosOntario Institute for Cancer Research
Paul C BoutrosUniversity of Toronto
Paul C BoutrosUniversity of Toronto
Gail P RisbridgerMonash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
Robert G BristowPrincess Margaret Cancer Centre, University Health Network
Robert G BristowUniversity of Toronto
  • 1 - 33

Datasets

Release 1.2